Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | GALR2 | O43603 | 1/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4284552 | 0.83 | LMNA (0.45) | LMNASMN1; SMN2ALDH1A1POLBHCAR3 | |
| SCHEMBL546991 | 0.82 | NPSR1 (0.43) | LMNASMN1; SMN2ALDH1A1KCNMA1POLB | |
| SCHEMBL13544467 | 0.82 | L3MBTL1 (0.43) | LMNAL3MBTL1ALDH1A1POLBHCAR3 | |
| Hydrochloric Acid SCHEMBL3467163 | 0.81 | NPSR1 (0.42) | LMNASMN1; SMN2ALDH1A1KCNMA1POLB | |
| SCHEMBL182687 | 0.78 | LMNA (0.41) | LMNAL3MBTL1HCAR3 | |
| SCHEMBL7514225 | 0.77 | KMT2A (0.49) | LMNASMN1; SMN2L3MBTL1ALDH1A1HCAR3 | |
| SCHEMBL3060652 | 0.77 | GPR35 (0.40) | LMNASMN1; SMN2ALDH1A1KCNMA1MAPT | |
| SCHEMBL3431418 | 0.77 | KCNMA1 (0.43) | LMNASMN1; SMN2L3MBTL1ALDH1A1KCNMA1 | |
| SCHEMBL953645 | 0.76 | MAPT (0.58) | LMNASMN1; SMN2ALDH1A1POLBMAPT | |
| Propane SCHEMBL18131179 | 0.76 | HCAR3 (0.38) | LMNAL3MBTL1ALDH1A1HCAR3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004243-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004243-A1 | PHARMACEUTICAL COMPOUNDS | CDK1, CDK2, CDK4 | SLC6A2 1702/4885SLC6A4 750/4885SLC6A3 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.